Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin L Marcar, NJ MacLaine, TR Hupp, DW Meek Cancer research 70 (24), 10362-10370, 2010 | 192 | 2010 |
p53-dependent repression of polo-like kinase-1 (PLK1) L McKenzie, S King, L Marcar, S Nicol, SS Dias, K Schumm, P Robertson, ... Cell cycle 9 (20), 4200-4212, 2010 | 135 | 2010 |
Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma C Hogan, C Hutchison, L Marcar, D Milne, M Saville, J Goodlad, ... Journal of biological chemistry 283 (26), 18012-18023, 2008 | 111 | 2008 |
MAGE-A antigens as targets in tumour therapy DW Meek, L Marcar Cancer letters 324 (2), 126-132, 2012 | 102 | 2012 |
Radiation resistance in KRAS-mutated lung cancer is enabled by stem-like properties mediated by an osteopontin–EGFR pathway M Wang, J Han, L Marcar, J Black, Q Liu, X Li, K Nagulapalli, LV Sequist, ... Cancer research 77 (8), 2018-2028, 2017 | 97 | 2017 |
FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53 AM Ochocka, P Kampanis, S Nicol, N Allende-Vega, M Cox, L Marcar, ... FEBS letters 583 (4), 621-626, 2009 | 73 | 2009 |
Acquired resistance of EGFR-mutated lung cancer to tyrosine kinase inhibitor treatment promotes PARP inhibitor sensitivity L Marcar, K Bardhan, L Gheorghiu, P Dinkelborg, H Pfäffle, Q Liu, ... Cell reports 27 (12), 3422-3432. e4, 2019 | 56 | 2019 |
MAGE-A cancer/testis antigens inhibit MDM2 ubiquitylation function and promote increased levels of MDM4 L Marcar, B Ihrig, J Hourihan, SE Bray, PR Quinlan, LB Jordan, ... PloS one 10 (5), e0127713, 2015 | 56 | 2015 |
PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53 Q Liu, L Gheorghiu, M Drumm, R Clayman, A Eidelman, MF Wszolek, ... Oncogene 37 (21), 2793-2805, 2018 | 55 | 2018 |
Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas L Mundo, L Del Porro, M Granai, MC Siciliano, V Mancini, R Santi, ... Modern Pathology 33 (12), 2407-2421, 2020 | 54 | 2020 |
The presence of a high peak feature within low-average shear stimuli induces quiescence in venous endothelial cells M Franzoni, DT O’Connor, L Marcar, D Power, MA Moloney, ... Annals of Biomedical Engineering 48, 582-594, 2020 | 7 | 2020 |
The effect of serum starvation on tight junctional proteins and barrier formation in Caco-2 cells AM Ross, DR Walsh, RM Cahalane, L Marcar, JJE Mulvihill Biochemistry and Biophysics Reports 27, 101096, 2021 | 6 | 2021 |
Identification of nanoparticle properties for optimal drug delivery across a physiological cell barrier AM Ross, RM Cahalane, DR Walsh, AM Grabrucker, L Marcar, ... Pharmaceutics 15 (1), 200, 2023 | 2 | 2023 |
A SPP1-EGFR pathway links stem-like properties of KRAS-mutated lung cancer to radiation resistance M Wang, J Han, L Marcar, J Black, Q Liu, X Li, K Nagulapalli, LV Sequist, ... Cancer Research 77 (13_Supplement), 4756-4756, 2017 | | 2017 |
PARP1 Inhibition Radiosensitizes A Subset Of Genotype-Defined Bladder Cancers Through Modulation Of Reactive Oxygen Species H Willers, Q Liu, JA Efstathiou, L Gheorghiu, MR Drumm, RH Clayman, ... International Journal of Radiation Oncology, Biology, Physics 96 (2), S237-S238, 2016 | | 2016 |
Inhibition of p53 tumour suppressor function by tumour associated MAGE-A proteins LN Marcar University of Dundee, 2009 | | 2009 |